L-Optic (Levofloxacin)

Levofloxacin exerts its antibacterial effect by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. These enzymes are essential for DNA replication and transcription. By binding to their ATP‑binding sites, levofloxacin prevents DNA supercoiling and strand separation, leading to bacterial cell death. This mechanism provides broad‑spectrum activity against Gram‑positive and Gram‑negative ocular pathogens.

The dosing regimen for L‑Optic is determined by the prescribing ophthalmologist based on the specific infection, severity, and patient factors. Typical regimens involve one to several drops instilled into the affected eye(s) at defined intervals, such as every two to four hours initially, followed by a reduced frequency. The exact dose and duration must be individualized and written on the prescription.

Safety data for levofloxacin ophthalmic use during pregnancy or lactation are limited. Because systemic absorption can occur, the drug should be used only if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers should evaluate the risk‑benefit profile and consider alternative treatments when possible.

To place an order, visit the product page for L‑Optic on the GNH India website (gnhindia.com) and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

L‑Optic’s active ingredient, levofloxacin, belongs to the fluoroquinolone class, offering broad‑spectrum coverage against many Gram‑positive and Gram‑negative bacteria, including some resistant strains. Compared with older agents such as chloramphenicol or macrolides, levofloxacin often provides faster bacterial eradication and a lower risk of resistance development, though it may carry a higher risk of tendon‑related adverse events.

L‑Optic should be stored at room temperature, preferably below 25 °C, in its original container to protect it from moisture and direct sunlight. Keep the vial tightly closed when not in use and avoid freezing. If the product appears discolored or contains particles, discard it and obtain a new supply.

L‑Optic is applied topically to the eye as an ophthalmic solution. The patient should wash their hands, tilt the head back, and pull down the lower eyelid to create a small pocket. One or more drops are instilled into the conjunctival sac as prescribed, avoiding contact between the tip of the bottle and the eye or any surface to maintain sterility.

The most serious adverse reactions to levofloxacin eye drops include corneal ulceration or worsening of existing corneal lesions, severe allergic responses such as anaphylaxis, and systemic tendon rupture, although the latter is rare. Patients should be instructed to seek immediate medical attention if they experience intense eye pain, sudden vision loss, swelling of the eyelids, or systemic tendon pain.

L‑Optic should be avoided in individuals with a documented hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the ophthalmic formulation. Caution is also advised for patients with a history of tendon disorders, myasthenia gravis, or those taking concomitant systemic fluoroquinolones, as the risk of adverse effects may be heightened.